Business Context and Reporting Period
This Form 6-K filing by Therapix Biosciences Ltd. (not Scisparc Ltd.) covers the month of January 2021, specifically dated January 6, 2021. The report details the status of a Special General Meeting of Shareholders convened on January 6, 2021, which was adjourned due to a lack of quorum.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a procedural report regarding a shareholder meeting and contains no financial statements or performance metrics.
Material Changes
No material financial changes versus a prior comparable period are reported in this filing. The primary event is the procedural adjournment of the Special Meeting from January 6, 2021, to January 7, 2021.
Guidance, Outlook, and Management Commentary
- Meeting Adjournment: The Special Meeting was adjourned to Thursday, January 7, 2021, at 8:00 a.m. Eastern Time (3:00 p.m. Israel time).
- Format: The Adjourned Special Meeting will be held virtually via Zoom videoconference.
- Quorum Rules: If a quorum is not present within half an hour of the start time, any number of shareholders present in person, by proxy, or via proxy card will constitute a quorum.
- Proxy Voting: Proxy cards delivered for the original Special Meeting will be voted at the Adjourned Special Meeting.
- Registration: Shareholders wishing to participate must register by emailing a notice of attendance to the Chief Financial Officer, Mr. Oz Adler, by 7:00 a.m. Eastern Time on January 7, 2021.
Key Facts for Investor Verification
- Verify the outcome of the Adjourned Special Meeting scheduled for January 7, 2021.
- Confirm the specific matters proposed for shareholder vote, which are not detailed in this specific Form 6-K text.
- Note that the registrant name is Therapix Biosciences Ltd., not Scisparc Ltd.
- Check subsequent filings for the results of the shareholder vote and any resulting corporate actions.